Better tech for mental health
The Fisher Wallace neurostimulation device is cleared by the FDA to treat depression, anxiety, and insomnia. In clinical trials, the majority of patients experience relief within two weeks. Simply use the device at home for 20 minutes, once or twice a day. Return it for a full refund within 30 days if your symptoms are not significantly reduced.
The brain is an electrical system
Our technology works by treating the brain electrically to reduce the symptoms of depression, anxiety and insomnia.
During each treatment session, the Fisher Wallace device stimulates the brain to release neurochemicals needed for healthy mood and sleep, reduce cortisol and regulate brainwave activity. Founded in 2007, Fisher Wallace Labs now has over 100,000 patients who have used our device, and over 14,000 doctors and providers who have prescribed our device.
Many of the people helped by our technology previously found drug therapy to be insufficient or they wanted to avoid the side effects of medication altogether. The Fisher Wallace device may be used safely in conjunction with medication or as a standalone therapy.
Why patients try our technology
Drug therapy helps, but it's not enough for me
Our device is safe to use in conjunction with medication.
I've tried multiple medications, but can't find relief
Our device often works when medication has failed.
Fisher Wallace has invested millions of dollars in clinical research, including three large trials conducted during the pandemic and a pilot study at Mount Sinai Beth Israel Hospital (see graph) which found the Fisher Wallace Stimulator® to be successful in treating depression. Our most recent study launched In January 2022 - an anxiety and stress reduction program enrolling 200 uniformed police officers in the Seattle Police Department.
Affordable mental healthcare
A one-time purchase that costs less than a few talk therapy sessions.
Fully refundable within first 30 days if you aren't completely satisfied.
Free shipping and free returns on all orders.
Device purchase is eligible for FSA and HSA reimbursement.
Prescribed by over 14,000 doctors
I have had great success using the device to treat severe, chronic insomnia in patients who are resistant to pharmacotherapy. Also, patients who seek a drug-free alternative to treat insomnia have used the Fisher Wallace Stimulator to reduce or eliminate their dependence on drugs.— Andres San Martin, M.D., Assistant Clinical Professor of Psychiatry, Columbia University
I have been using the Fisher Wallace Stimulator for about 5 years to help with anxiety and it has been a blessing over the years. I recommend this device to anyone with anxiety issues.— Michael H., Fisher Wallace Customer
In the news
"Columbia University Associate Clinical Professor of Psychiatry Richard P. Brown says he has used the device with 400 severely depressed patients and that more than 70% find relief, about twice the rate of anti-depressants."
"But since I couldn't stop talking about my good mood and hypercharged focus, my friends stopped laughing and started asking if they could borrow it. I'm reluctant to let go of my stimulator, however."
"5 Health-Tech Startups to Watch in 2021."
"One of four technologies innovating mental health."
Fisher Wallace is helping the Seattle Police Department to "normalize access to self-care."
"The Fisher Wallace device...turned out to be the most impactful intervention in all my antidepressant exploration. At $499, it was an investment, but considering that most people with depression seek therapeutic treatments often not covered by health insurance, the possible savings on therapy and drugs over my lifetime seemed to justify the expense."
We are a patient-owned company
Thousands of our customers and other individual investors own 15% of Fisher Wallace Labs. In total, we have raised over $7 million in capital on StartEngine, the leading SEC-regulated equity crowdfunding platform, and another $2.75 million through traditional venture capital.
We invite you to find out more about our current equity crowdfunding campaign and the opportunity to own shares in our company.